Gritstone Oncology Inc. (NASDAQ:GRTS) went down by -3.96% from its latest closing price compared to the recent 1-year high of $35.20. The company’s stock price has collected -1.62% of loss in the last five trading sessions. Press Release reported on 03/29/21 that Gritstone Announces First Person Dosed with its Second-Generation COVID-19 Vaccine in Phase 1 Study Conducted and Supported by NIAID/IDCRC
Is It Worth Investing in Gritstone Oncology Inc. (NASDAQ :GRTS) Right Now?
Opinions of the stock are interesting as 3 analysts out of 4 who provided ratings for Gritstone Oncology Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $25.33. GRTS currently public float of 37.75M and currently shorts hold a 8.15% ratio of that float. Today, the average trading volume of GRTS was 3.38M shares.
GRTS’s Market Performance
GRTS stocks went down by -1.62% for the week, with a monthly drop of -28.45% and a quarterly performance of 138.57%, while its annual performance rate touched 59.18%. The volatility ratio for the week stands at 10.72% while the volatility levels for the past 30 days are set at 9.00% for Gritstone Oncology Inc.. The simple moving average for the period of the last 20 days is -22.65% for GRTS stocks with a simple moving average of 43.66% for the last 200 days.
Analysts’ Opinion of GRTS
Many brokerage firms have already submitted their reports for GRTS stocks, with Robert W. Baird repeating the rating for GRTS by listing it as a “Underperform.” The predicted price for GRTS in the upcoming period, according to Robert W. Baird is $8 based on the research report published on January 20th of the current year 2021.
Robert W. Baird, on the other hand, stated in their research note that they expect to see GRTS reach a price target of $17. The rating they have provided for GRTS stocks is “Outperform” according to the report published on July 26th, 2019.
GRTS Trading at -33.67% from the 50-Day Moving Average
After a stumble in the market that brought GRTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.41% of loss for the given period.
Volatility was left at 9.00%, however, over the last 30 days, the volatility rate increased by 10.72%, as shares sank -29.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -64.18% lower at present.
During the last 5 trading sessions, GRTS fell by -1.62%, which changed the moving average for the period of 200-days by +45.80% in comparison to the 20-day moving average, which settled at $12.35. In addition, Gritstone Oncology Inc. saw 146.45% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at GRTS starting from Rousseau Raphael, who sale 10,000 shares at the price of $25.07 back on Jan 20. After this action, Rousseau Raphael now owns 0 shares of Gritstone Oncology Inc., valued at $250,705 using the latest closing price.
Rousseau Raphael, the See Remarks of Gritstone Oncology Inc., sale 20,000 shares at $17.53 during a trade that took place back on Jan 19, which means that Rousseau Raphael is holding 0 shares at $350,564 based on the most recent closing price.
Stock Fundamentals for GRTS
Current profitability levels for the company are sitting at:
- -2626.13 for the present operating margin
The net margin for Gritstone Oncology Inc. stands at -2608.72. The total capital return value is set at -60.64, while invested capital returns managed to touch -61.71. Equity return is now at value -93.50, with -64.50 for asset returns.
Based on Gritstone Oncology Inc. (GRTS), the company’s capital structure generated 15.05 points at debt to equity in total, while total debt to capital is 13.08. Total debt to assets is 11.33, with long-term debt to equity ratio resting at 11.53. Finally, the long-term debt to capital ratio is 10.02.
When we switch over and look at the enterprise to sales, we see a ratio of 0.73, with the company’s debt to enterprise value settled at 8.53. The receivables turnover for the company is 16.75 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.50.